Enzyme-linked Immunosorbent Assay Market size is predicted to cross USD 27 billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of enzyme-linked immunosorbent assay was over USD 12 billion.
The growth of this sector can be primarily attributed to the increasing incidence of chronic diseases worldwide. Enzyme-linked immunosorbent assay plays a significant role in detecting, monitoring, and treating these health issues resulting in enhanced patient outcomes. The cases of chronic diseases globally are expected to grow by 57% by the end of 2025 report as per a report by the World Health Organization This escalating health crisis underscores the critical need for advanced diagnostic tools like ELISA in effectively managing and combating these ailments.
The development of enzyme immunoassays by major industry players contributes to the market's expansion. To identify IgA and IgM antibodies against four SARS-CoV-2 antigens, for example, Bio-Rad introduced the Bio-PlexPro Human IgA and IgM SARS-CoV-2 panels in September 2021. The multiplex immunoassay panels aided in the assessment of therapeutic efficacy by the vaccine developers during the development, clinical, and post-marketing phases.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
6% |
|
Base Year Market Size (2023) |
USD 12 Billion |
|
Forecast Year Market Size (2036) |
USD 27 Billion |
|
Regional Scope |
|
Type (Indirect ELISA, Sandwich ELISA)
In enzyme-linked immunosorbent assay market, sandwich ELISA segment is likely to account for around 62% share by 2036. Collaborations between academic institutions, biotechnology companies, and pharmaceutical firms foster innovation in biomarker research, thus, Sandwich ELISA, being a cornerstone in this field, benefits from such partnerships.
The shared expertise and resources in collaborative projects contribute to the development and validation of sandwich ELISA assays, further propelling its market growth. A study found that strategic collaborations in the life sciences industry have increased by over 30% in recent years. The growth of the sandwich ELISA segment is further driven by the rising demand for cancer biomarkers, advancements in precision medicine, increasing investment in biomarker research, the clinical emphasis on disease monitoring, growing pharmaceutical research activities, and strategic alliances and collaborations in the life sciences industry.
End User (Hospitals, Pharmaceutical, Research & Academic Institutions)
In terms of end users, the hospital segment is likely to cross a significant share during the studied period. The shift towards personalized medicine involves tailoring medical decisions and interventions based on individual patient characteristics.
Hospitals are increasingly adopting personalized approaches to improve treatment efficacy, leading to the growth of personalized medicine as a paradigm in healthcare that contributes to the continued use of ELISA in hospital settings. The global personalized medicine sales are projected to reach USD 3.2 trillion by 2027, according to a report.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End User |
|
North American Market Statistics
The enzyme-linked immunosorbent assay market in the North America region is assessed to witness the largest revenue share of 35% during the forecast period. North America is witnessing a rise in the prevalence of chronic diseases, contributing to increased healthcare expenditures and a focus on early detection.
The demand for advanced diagnostic tools like ELISA is fueled by the imperative to address the growing burden of chronic diseases in the region. Based on statistics in 2020, there will be approximately 2,281,658 cases of cancer in the United States overall year 2020. By 2040, the number is predicted to increase to 3,123,452 instances. North America is at the forefront of technological advancements in healthcare, and the IVD sector is no exception.
APAC Market Analysis
Enzyme-linked immunosorbent assay market in the Asia Pacific is assumed to expand notably registering a growth worth 28% during the studied period. Government initiatives aimed at enhancing healthcare access contribute to the growth of the enzyme-linked immunosorbent assay market in the region. As healthcare becomes more accessible to a larger population, the demand for diagnostic tools like ELISA increases.
Government-backed programs focused on preventive healthcare and disease management create a conducive environment for the adoption of advanced diagnostic technologies, further supporting the growth of the ELISA market. Therefore, many countries from the APAC region have introduced programs and initiatives related to healthcare.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?